Tenax Therapeutics

Tune in today, at 3:45 p.m. ET to watch Tenax CEO, Chris Giordano, present at the Needham Virtual Healthcare Conference. Listen to the webcast here: https://bit.ly/4cmdTCp #pulmonaryhypertension #Group2PH

Attending #ACC25? Connect with Tenax management at this week’s American College of Cardiology conference to learn more about recent updates in our our Phase 3 LEVEL program, advancing TNX-103 (oral levosimendan) for the treatment of PH-HFpEF. #ACC25 #pulmonaryhypertenstion #Group2PH

Today, we reported fourth quarter and full year 2024 financial results and highlighted recent updates. For full details and results, read today’s press release: https://bit.ly/4ce1bpq

Tune in today at 3:40 p.m. ET to watch Tenax CEO, Chris Giordano, and CMO, Dr. Stuart Rich participate in a fireside chat at the Leerink Partners 2025 Global Healthcare Conference. Listen to the webcast here: https://bit.ly/41rf8LI #pulmonaryhypertenstion #Group2PAH

We are pleased to provide an update on our Phase 3 LEVEL Program. We are advancing two TNX-103 (oral levosimendan) registrational studies for the treatment of PH-HFpEF. To read the full release, click here: http://bit.ly/4haPDE0 This morning we also announced a $25 million financing from a new top-tier healthcare investor, RTW Investments, LP. This funding will enable us to advance our registrational studies for TNX-103 and solidify our strategy to bring this novel cardiopulmonary therapy to patients with a high unmet need. To read the full release, click here: https://bit.ly/4ku44pB #pulmonaryhypertenstion #Group2PAH

In the final part of Tenax Therapeutics’ LEVEL Setting Series, Dr. Javed Butler (Baylor Scott & White) discusses the disease prevalence and reason to address significant unmet Need in patients with PH-HFpEF. To listen to the first five parts, please click here: https://lnkd.in/epc94aUu.

In Part 5 of Tenax Therapeutics’ LEVEL Setting Series, Dr. Barry Borlaug (Mayo Clinic) discusses treatment with Oral Levosimendan therapy in the HELP open label extension study. To listen to the first four parts, please click here: https://lnkd.in/epc94aUu.

In Part 4 of Tenax Therapeutics’ LEVEL Setting Series, Dr. Barry Borlaug (Mayo Clinic) discusses the impact of IV Levosimendan therapy on hemodynamics and exercise dynamics from the HELP Study. To listen to the first three parts, please click here: https://lnkd.in/epc94aUu.

In Part 3 of Tenax Therapeutics’ LEVEL Setting Series, Dr. Daniel Burkhoff (Cardiovascular Research Foundation) discusses the key observations from the Levosimendan Phase 2 HELP study and Levosimendan’s mechanism of action for the treatment of PH-HFpEF. To listen to Parts 1 & 2, please click here: https://lnkd.in/d9vRi9ym. 

In Part 2 of Tenax Therapeutics’ LEVEL Setting Series, Dr. Sanjiv Shah (Northwestern University) discusses if PH-HFpEF is treatable. To listen to Part 1, please click here: https://lnkd.in/d9vRi9ym.